医学
重症肌无力
多导睡眠图
麻醉
多导睡眠图
睡眠呼吸暂停
持续气道正压
内科学
肌肉无力
通气不足
阻塞性睡眠呼吸暂停
队列
统计显著性
呼吸
呼吸暂停
呼吸系统
气道正压
置信区间
睡眠(系统调用)
唑吡坦
呼吸道疾病
交叉研究
不宁腿综合征
神经肌肉疾病
心脏病学
作者
Bradley V. Vaughn,Shakeel Tabish,James F. Howard
摘要
INTRODUCTION: Autoimmune Myasthenia Gravis (MG) is associated with obstructive sleep apnea. Muscle-specific kinase antibody positive MG (MuSK-ab+ gMG) patients often have more bulbar weakness than MuSK antibody negative (MuSK-ab-) patients, but data comparing sleep-related breathing disorders is scarce. METHODS: Utilizing the University of North Carolina Myasthenia Gravis Registry, 30 MuSK-ab+ generalized MG (gMG) patients (26 female, 4 male) were matched with 30 MuSK-ab- gMG patients for age, sex, and Myasthenia Gravis Foundation of America (MGFA) clinical class. Additionally, 30 MuSK-ab- ocular MG patients were matched for age and sex. Features of sleep-related symptoms, sleep diagnosis, polysomnogram findings, need for positive airway pressure (PAP) and chronic nocturnal supplemental oxygen were analyzed. Statistical significance was determined using Chi-square test with 95% confidence intervals and Student T test (p < 0.05). RESULTS: MuSK-ab+ MG patients had a higher prevalence of sleep related breathing disorders than the two comparative groups (Odds Ratio [Confidence Interval] 4.97 [1.39-17.82], 3.82 [1.15-12.71], respectively) and for obstructive sleep apnea in MuSK-ab+ gMG vs. MuSK-ab- gMG (4.33 [1.20-15.61]). MuSK-ab+ patients had higher rates of sleep related hypoventilation than MuSK-ab- groups (8.8 [1.01-76.96], 19.46 [2.18-2574]) and requirement for bilevel PAP and nocturnal supplemental oxygen (Odds ratio for both groups, 23.04 [2.63-3037], 23.0 [2.63-3037]). DISCUSSION: Our cohort suggests MuSK-ab+ patients are more likely to have sleep-related breathing disorders independent of MGFA class, age, and sex. Given the long-term health risks of sleep-related breathing disorders, we suggest clinicians perform routine sleep screening with a low threshold for in-laboratory polysomnography.
科研通智能强力驱动
Strongly Powered by AbleSci AI